Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein by unknown
Mouse Complement Regulatory  Protein Crry/p65 
Uses the Specific Mechanisms of Both Human 
Decay-accelerating  Factor and Membrane Cofactor 
Protein 
By Youn-Uck Kim,* Taroh Kinoshita,* Hector Molina,~ 
Dennis  Hourcade,r  Tsukasa  Seya,$  Lynne M.  Wagner,~ 
and V.  Michael  HolersU 
From the  *Department of Immunoregulation, Research Institute for Microbial Diseases, Osaka 
University, 565 Osaka, Japan;  the *Department of Medicine, Washington University School of 
Medicine, St.  Louis, Missouri 63130; the $Center for Adult Diseases, 537 Osaka, Japan; and 
the lIDepartments of Medicine and Immunology,  Division of Rheumatology,  University of 
Colorado Health Sciences Center, Denver, Colorado 80262 
Summary 
Normal host cells are protected from the destructive action of complement by cell surface com- 
plement regulatory proteins. In humans, decay-accelerating factor (DAF) and membrane cofactor 
protein (MCP) play such a biologic role by inhibiting C3 and C5 convertases. DAF and MCP 
accomplish this task by specific mechanisms designated decay-accelerating  activity and factor I 
cofactor  activity,  respectively.  In other species, including mice, structural and/or functional 
homologues of these proteins are not yet well characterized.  Previous studies have shown that 
the mouse protein Crry/p65 has certain characteristics of self-protecting complement regulatory 
proteins. For example, Crry/p65 is expressed on a wide variety of murine cells, and when expressed 
on human K562 erythroleukemic cells, it prevents deposition of mouse C3 fragments on the 
cell surface during activation of either the classical or alternative complement pathway. We have 
now studied factor I cofactor and decay-accelerating activities of Crry/p65. Recombinant Crry/p65 
demonstrates cofactor activity for factor I-mediated cleavage of both mouse C3b  and C4b. 
Surprisingly, Crry/p65 also exhibits decay-accelerating  activity for the classical  pathway C3 convertase 
strongly and for the alternative pathway C3 convertase weakly. Therefore, mouse Crry/p65 uses 
the specific mechanisms of both human MCP and DAF.  Although Crry/p65, like MCP and 
DAF, contains tandem short consensus repeats (SCtL) characteristic of C3/C4 binding proteins, 
Crry/p65 is not considered to be a genetic homologue of either MCP or DAF. Thus, Crry/p65 
is an example of evolutionary conservation of two specific activities in a single unique protein 
in one species that are dispersed to individual proteins in another. We propose that the repeating 
SCR motif in this family has allowed this unusual process of evolution to occur, perhaps driven 
by the use of MCP and DAF as receptors by human pathogens such as the measles virus. 
N 
' ormal cells are protected from the inadvertent destruc- 
tive action of complement primarily by the activities 
of intrinsic membrane regulatory proteins (1). These regula- 
tory proteins act either at the early C3/C5 convertase steps 
or during the later assembly of the membrane attack com- 
plex (MAC) 1. In humans, two membrane regulatory pro- 
1 Abbreviations used in this paper: CR, complement receptor; DAF, decay- 
accelerating factor; GPI, glycophosphatidylinositol;  LHR, long homologous 
repeat; M, mouse; MAC, membrane attack complex; MCP, membrane 
cofactor protein; PNH, paroxysmal nocturnal hemoglobinuria; RCA, 
regulators of complement activation; SCR, short consensus repeat. 
teins are present that act on C3/C5 convertases. These pro- 
teins  are  decay-accelerating  factor  (DAF,  CD55)  (2)  and 
membrane cofactor protein (MCP,  CD46) (3). 
DAF and MCP each use a unique mechanism to accom- 
plish self protection of cells. DAF acts by blocking conver- 
tase assembly and accelerating the spontaneous decay of C2a 
and Bb from C4b and C3b, respectively (4). MCP, conversely, 
has no decay-accelerating activity but rather acts as a required 
cofactor for factor I-mediated cleavage of C3b and C4b (5). 
Factor 1-cleaved forms of C3b and C4b have no further hemo- 
lytic or complement activating capacity. Using these two dis- 
tinct mechanisms, DAF and MCP together exert a substan- 
tial capacity to block further complement activation on cell 
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pathway. 
The biologic importance of membrane complement inhibi- 
tory proteins  has  been demonstrated  by observations in  a 
number of human diseases. One example is paroxysmal noc- 
turnal hemoglobinuria (PNH) (6). PNH is an acquired so- 
matic cell disorder manifest in bone marrow lineage cells. 
Somatic mutations in the PIG-A  gene found on the X chro- 
mosome  result  in  absent  or  substantially  lower  levels  of 
glycophosphatidylinositol (GPI)-anchored proteins in patients 
with PNH (7). Two membrane complement regulatory pro- 
teins,  DAF and CD59 (a MAC inhibitor)  use GPI anchors 
for membrane attachment  (8,  9). The absence of DAF and 
CD59 in PNH results in the spontaneous hemolysis of erythro- 
cytes due to the relatively unchecked activity of the alterna- 
tive complement pathway. 
A more complete understanding  of the biologic roles of 
these proteins would result from the analysis of their homo- 
logues in other species, especially the mouse. DAF and MCP 
are members of a gene family designated the regulators  of 
complement activation (R.CA)  (10). RCA genes are charac- 
terized by the presence in the derived protein  sequence of 
a repetitive motif "~60-70 amino acids in length that is desig- 
nated a short consensus repeat  (SCR).  SCRs contain  four 
invariant cysteines and one tryptophan in addition to other 
highly conserved but not invariant  amino adds. In the mouse, 
analysis  of the RCA genes and their products has revealed 
a number of significant  differences as compared with humans. 
In particular,  no genes or cDNAs with enough nucleotide 
similarity to either DAF or MCP have been able to be identified 
in cross species screening despite many attempts (11, 12). In 
addition,  two other RCA proteins,  complement  receptors 
1 and 2 (CR1 and CR2), are derived by different molecular 
mechanisms (12-14).  Human CR2 and CR1 are the prod- 
ucts of unique genes (10),  while mouse CR2 (MCR2) and 
a CR1 homologue (MCR1)  found on B lymphocytes and 
follicular dendritic cells (FDCs) are the products of alterna- 
tively spliced RNA derived from the single Cr2 gene. 
With regard to potential DAF and MCP homologues, based 
on a number of lines of evidence we have previously pro- 
posed that one mouse RCA family gene, Crry, encodes a func- 
tional homologue of mouse DAF or MCP (11, 12, 15). The 
Crry gene was originally identified using cDNA probes for 
human CR1 (16,  17). As opposed to human CR.1,  though, 
Crry-derived mRNA and protein are widely distributed (15, 
16,  18). Expression of the recombinant  Crry cDNA in the 
human  K562 cell line results in a protein recognized by a 
rabbit polyclonal antibody prepared using human CR1 as an 
immunogen (12). This antisera had been used previously to 
identify and partially characterize a mouse protein called p65 
(19).  Because of these results, we have since designated the 
protein product  of the Crry gene Crry/p65.  We have  also 
found that Crry/p65 cannot act as a receptor for mouse C3b- 
or human  C4b-coated erythrocytes (12).  However, recom- 
binant Crry/p65 protein is able to block activation of both 
the  mouse  classical  (12)  and  alternative  (20)  complement 
pathways. Several rat mAbs that react with Crry/p65 can re- 
verse classical complement pathway control on cell membranes 
in which recombinant  Crry/p65  is expressed (15). 
The specific mechanisms by which Crry/p65 can control 
complement  activation  have  not  been previously  defined. 
Herein,  we  demonstrate  that  Crry/p65  has  both  decay- 
accelerating and cofactor activities. Thus, this one mouse pro- 
tein encompasses the complement regulatory activities of both 
human DAF and MCP. Based on these results and a further 
comparative analysis of mouse and human RCA gene struc- 
tures,  we propose that  the repetitive nature  of this  SCR- 
containing family has allowed this unusual evolutionary pro- 
cess to occur. 
Materials and Methods 
Buffers and Reagents.  The following buffers were used: isotonic 
veronal buffer, pH 7.4, containing 72.7 mM NaC1, 2.5% dextrose, 
0.1% gelatin, 0.15 mM CaCI2, and 1 mM MgC12 (DGVB); and 
0.1% gelatin-veronal-buffered saline, pH 7.4, containing  10 mM 
EDTA (EDTA-GVB). Guinea pig C1 and C2 (21), human C3 and 
C4 (22), mouse factors H (23) and I (24), and mouse C3 (23) were 
purified as described elsewhere. Mouse C4 was partially purified 
from plasma by polyethylene glycol (PEG) fractionation,  QAE- 
Sephadex A-50 and Mono Q column chromatography. C4 was moni- 
tored by hemolytic assay, SDS-PAGE and Ouchterlony analysis with 
anti-mouse  C4 antiserum.  Purity of the final preparation can be 
evaluated from Fig. 2. Mouse factor B was also partially purified 
from the same plasma. In fractions obtained from the above men- 
tioned QAE-Sephadex A-50 cohmn, factor B was detected by hemo- 
lytic assay. Factor B was further purified by DEAE-Sephacd cohmn. 
Partially purified factor B was cleavable  by factor D plus C3b, and 
its identity  was confirmed by amino acid sequence. 
Purification of Recombinant Soluble Crry/ta55 (rsCrry/p65).  rsCrry/ 
p65 was purified to homogeneity by sequential column chroma- 
tography  as previously described (20) from  the  supernatant  of 
Trichoplasia ni cells (Invitrogen Corp., San Diego, CA) infected with 
baculovirus encoding a soluble form of Crry/p65.  rsCrry/p65  in- 
dudes the complete extracytoplasmic domain 5 SCRs of Crry/p65 
and is  truncated  after  the  last cysteine of SCR 5.  Before use, 
rsCrry/p65  was dialyzed into DGVB buffer. 
Extracts ofK562 Erythroleukeraic Cells Extrressing Crry/p65, MCR1 
or MCRZ  K562 cells transfected with Crry cDNA, antisense Crry 
cDNA, MCR1 cDNA, and MCR2 cDNA as described previously 
were used as sources of recombinant  proteins (12). Transfectants 
were cultured in KPMI 1640 containing 10% FCS and 400 #g/ml 
G418 (Geneticin; GIBCO BILL, Gaithersburg, MD). For extrac- 
tion the cells were washed with PBS and incubated at 107/ml in 
PBS containing 0.5% NP-40 and 1 mM PMSF at room tempera- 
ture for 15 rain followed by centrifugation  at 1,500 rpm for 10 
rain and then 12,000 rpm for 5 rain. The supernatants were stored 
frozen at  -80~ 
Assay of  Factor I Cofactor Activity.  C3 and C4 were labeled with 
125I (DuPont, Wilmington,  DE) in IODOGEN (Pierce, Rockford, 
IL)-coated test tubes (25). The preparations had specific activities 
of 106-5 x  106 cpm/#g protein and were active after iodination. 
Antibody-sensitized sheep erythrocytes (EA cells) bearing C1 (EAC1 
cells) were prepared by incubation of EA cells (10S/ml) with guinea 
pig C1 (200 U/m1) for 15 rain at 30~  EAC14 cells bearing human 
or mouse C4b were prepared by incubating  EAC1 cells (10S/ml) 
with an equal volume of human C4 or mouse C4 (10/~g/ml) for 
20 rain at 30~ 
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natant by incubating 12sI-C3 at 0.5 #g/ml with 5  x  107 EAC142 
cells/ml in DGVB at 30~  for 15 rain. A mixture of 12SI-labeled 
C3b (100 ng/ml), factor I (200 ng/ml), and cell extracts (4  x  10  s 
cell equivalents/ml) was incubated for 50 rain at 37~  Cleavage 
of the oe' chain of C3b was assessed by SDS-PAGE under reducing 
conditions  followed by autoradiography. 
Partially purified mouse C4 was radiolabeled and incubated with 
EAC1 cells to convert C4 to C4b. The resulting EAC14 cells were 
hypotonically lysed and the ghosts were extracted with 0.5% NP-40. 
This extract was used as a source of cell-bound C4b. The superna- 
tant obtained after incubation  of C4 with EAC1  cells was used 
as a source of fluid-phase C4b. These radiolabeled C4bs were in- 
cubated as above with mouse factor I in the presence of K562 de- 
tergent extracts as a source of cofactor. To eliminate any activity 
of K562-derived MCP, anti-MCP in mAb M177, previously shown 
to block human MCP cofactor activity in vitro (26), was included 
in  the cofactor assays at  10 #g/ml. 
Assay of Decay-accelerating  Activity for the Classical Pathway C3 
Convertase.  EAC142 cells were prepared by incubating EAC14 cells 
bearing mouse C4b with guinea pig C2 for 5 rain at 30~  The 
EAC142 cells were incubated,  for various durations of time as shown 
in Results,  at 30~  in the presence or absence of rsCrry/p65 to 
allow decay of C4b2a. The residual  C4b2a sites were assessed by 
incubating the cells with guinea pig serum in EDTA-DGVB as 
a source of C3-C9 for 60 min at 37~ 
Assay of  Decay-accelerating  Activity  for the Alternative Pathway C3 
Convertas~  EAC3b cells were prepared by incubating EAC142 cells 
(5  x  10S/m1) bearing  human  C4b  and  guinea  pig  C2a  with 
mouse C3 (70 #g/ml) for 30 min at 30~  followed by incubation 
with EDTA-containing buffer at 37~  for 2.5 h to inactivate C1 
and C2a. EAC3b cells (5  x  10S/ml) were incubated in MgEGTA- 
GVB with mouse B (30 #g/ml) and human D (2 #g/ml) for 5 rain 
at 30~  to prepare EAC3bBb cells. 
EAC3bBb cells were incubated for various times at 300C in the 
presence or absence of rsCrry/p65. The residual C3bBb sites were 
assessed by incubating the calls with rat serum in EDTA-DGVB 
as a source of C3-C9 for 60 rain at 37~ 
Mapping of Mouse Cr2 Exons Encoding SCRs I-6 of MCRI.  A 
genomic clone (M3) was isolated from a X fix II library of routine 
genomic DNA (14) with an MCR1 SCK 1-6 containing eDNA 
probe. X13 DNA was digested with several restriction enzymes 
and subjected to Southern blot analysis using MCK1 SCK-specific 
5' 32p-labeled oligonucleotides  (Table 1). M3 DNA fragments were 
subcloned with the pBSKS vector (Stratagene,  San Diego, CA) and 
their respective coding regions were sequenced using a strategy 
previouslyused to map exon-intron junctions of human CK2 (27) 
and CK1 (28).  Briefly, oligonucleotides from the 5' and 3' ends 
of each SCR were used to sequence across the 3' and 5' junctions, 
respectively.  Split  exons were confirmed, where necessary,  using 
oligonucleotides prepared using intron sequence.  Exons encoding 
SCR  1-5 and the NH2-terminal portion of SCR 6 were charac- 
terized. 
Results 
FactorlCofactorActivityofCrry/p65.  We initially expressed 
recombinant Crry/p65 in K562 human erythroleukemic ceUs 
and used their detergent extract as a source of Crry/p65.  As 
a negative control, we used detergent extracts of K562 cells 
expressing Crry cDNA in the antisense orientation.  For com- 
parison,  we also used detergent  extracts  of K562  cells ex- 
pressing MCR1  and  MCR2  cDNAs  as  sources  of MCR1 
and MCR2,  respectively. To further assure the origin of the 
cofactor activity, human MCP blocking mAb M177 was in- 
cluded  in  the  reactions. 
As shown  in Fig.  1,  mouse factor I  cleaved radiolabeled 
Table  1.  Cr2-derived  Oligonucleotides  for Exon-Intron Junctional Analysis 
Oligonucleotide  Sequence  Exon 
MC2.49  TGTAAGTTGCTGCCAAAGTA  1 
MC2.56  ACAGAACTGCTGAGCATCTGA  1 
MC2.50  CATGTATGAATCCTCAAGAA  2A 
MC2.101  ATTACAAGAATACGTAATTG  2A 
MC2.102  CGACTCATTGGTGACTCGTC  2B 
MC2.57  ACAAAGAGGCATATCATTAT  2B 
MC2.51  GAGTCACCTCCAGCCATCTC  3,4 
MC2.58  TACACTGAGGAGGTGGACTAT  3,4 
MC2.63  GCAGAGACAGCTTTTTCTATGGGATGGTAGTAACTT  3,4 
MC2.52  ATGCCAGAATTGAAAATGG  3,4 
MC2.65  CTAGAATAGCATGGTGCCAGCCAAACAGCAAATGGA  3,4 
MC2.53  TGTCTACCACCTCAAAATAT  5 
MC2.60  ACATGTCGGGACTGTATTGCT  5 
MC2.54  TGTGATGCAATTCCAAACCA  6A 
MC2.103  CACAAACAAAGGAAACCTCT  6A 
Oligonucleotides derived from the MCR1 cDNA nucleotide sequence used to identify genomic subclones and sequence across exon-intron junctions 
shown in Table 2. These sequence data are taken from reference 13. 
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Radiolabeled mouse C3b was incubated  with one of the cofactors  alone 
(lanes a.-d), or with a cofactor source plus mouse factor I (lanes e-h), or 
with factor I alone (lane i). Cleavage  of the et' chain of C3b was assessed 
by SDS-PAGE under reducing conditions with a 7.5% gel followed  by 
autoradiography. The cofactor sources are extracts of cells expressing 
Crry/p65 (lanes  a and e), antisense  construct  of Crry (lanes b andJ~, MCIL1 
(lanes c and g), or MCR2 (lanes  d and h). Molecular  sizes are on the left. 
mouse C3b in the presence but not in the absence of Crry/p65 
(Fig. 1, lanes e and i, respectively). This cofactor activity must 
be specific to Crry/p65 because the extract ofceUs expressing 
the anti-sense construct of Crry has no activity (Fig. 1, lane 
J). MCR1 showed strong and MCR2 showed weak cofactor 
activities (Fig.  1,  lanes g  and  h),  consistent with previous 
reports using purified native proteins (29-31).  The cleavage 
products  of the or' chain of mouse C3b  are the same with 
Crry/p65  and MCR1,  i.e.,  a'  70  and or'  43. 
We next  tested factor I cofactor activity of Crry/p65  in 
the cleavage of C4b. As shown in Fig. 2 (left),  the or' chain 
of cell-bound C4b  was cleaved by factor I  in  the presence 
of the extract of the cells expressing Crry/p65 (Fig. 2, lane 
b) but not the extract of the cells expressing antisense Crry 
(Fig. 2, lane c). The cleavage products of the a' chain appar- 
ently migrated with the dye-front. MCR1 and MCR2 had 
no detectable cofactor activity in C4b-cleavage (Fig. 2, lanes 
d and e). Analysis with fluid phase C4b gave a similar result 
(Fig.  2,  fight)  and demonstrated that  the or'  chain of C4b 
was cleaved only with Crry/p65 and factor I (Fig. 2, lane b'). 
Decay-accelerating Activity of Crry/p65.  To test decay-accel- 
erating activity of Crry/p65, it was necessary to use a strategy 
that would exclude hemolysis due to the presence of deter- 
gent during the study. To accomplish this, we used purified 
recombinant soluble Crry/p65 (rsCrry/p65) that lacks trans- 
membrane  and intracytoplasmic domains and is,  therefore, 
soluble in detergent-free conditions. Sheep erythrocytes bearing 
the classical pathway C3 convertase that contains mouse C4b 
(EAC14mo2  cells) were then incubated with buffer in the 
presence or absence of rsCrry/p65. At timed intervals an ali- 
quot was taken and further incubated with,  as a source of 
Figure 2.  Factor I cofactor  activity 
of  Crry/p65 in the cleavage  of  C4b. Ra- 
diolabeled cell-bound (left) and fluid- 
phase (right)  mouse  C4b were  incubated 
with mouse factor I and a cofactor. 
Cleavage of the a' chain of C4h was 
assessed  by SDS-PAGE  under reducing 
conditions  with a 10% gel followed  by 
autoradiography.  (Lanes a-e)  Cell- 
bound C4b; (lanes a'-e') fluid-phase 
C4b; (lanes  a and a') C4b alone; (lanes 
b and b'), Crry/p65 plus factor  I; (lanes 
c and c') extract of cells expressing an- 
tisense construct of Crry plus factor I; 
(lanes d and d') MCR1 plus factor I; 
(lanes  e and e') MCR2 plus  factor  I. Mo- 
lecular sizes are on the right. 
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Figure 3.  Acceleration of decay of the classical  pathway C3 convertase 
by recombinant  soluble Crry/p65. Sheep red cells bearing C4b2a com- 
plexes (EACI42 cells) were incubated with DGVB (O), buffer containing 
0.2/~g/ml Crry/p65 (@) or buffer containing 0.4/~g/ml Crry/p65 (X) 
at 30~  for 0-15 min to allow decay of the C3 convertases.  After the decay, 
remaining  C3 convertase was assessed  by incubating  the cells with C3-C9 
for 1 h at 37~  followed by centrifugation and spectrophotometric  mea- 
surement  of released hemoglobin. 
C3-C9, guinea pig serum diluted in EDTA-containing buffer. 
This allowed us to evaluate by hemolysis the C3 convertase 
activity remaining on the erythrocyte surface at the time of 
sampling. As shown in Fig. 3, rsCrry/p65 accelerated decay 
of the classical pathway C3 convertase strongly, decreasing 
the half-life from 7 rain to 1.2 min at 0.2/zg/ml and to 0.7 min 
at 0.4/~g/ml. 
We next tested decay-accelerating activity of Crry/p65 on 
the alternative pathway C3 convertases.  Sheep erythrocytes 
bearing C3bBb  complexes that consist of mouse C3b  and 
mouse Bb (Ec3bBb cells) were incubated with buffer in the 
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Figure 4.  Acceleration of decay of the alternative pathway C3 conver- 
tase by Crry/p65. Sheep red cells  bearing C3bBb complexes  (EC3bBb cells) 
were incubated with Mg-EGTA-GVB (O) or buffer containing 1/xg/ml 
Crry/p65 (@) or 2 I~g/ml Crry/p65 (X) at 30~  for 0-10 rain to allow 
decay of the C3 convertases. After the decay, remaining C3 convertase 
was assessed  by incubating  the cells with C3-C9 for 1 h at 37~  followed 
by centrifugation  and spectrophotometric measurement of released hemo- 
globin. 
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presence or absence of rsCrry/p65. At timed intervals an ali- 
quot was taken into a source of C3-C9,  rat serum diluted 
in EDTA-containing buffer, to evaluate the residual conver- 
tase activity by hemolysis. Without Crry/p65,  the alterna- 
tive C3 convertase decayed with a half-life of 3 min initially. 
After 3 min, stabilization of the convertase occurred most 
likely by properdin present in the samples  of complement 
components used to prepare EC3bBb cells. With rsCrry/p65, 
the decay curves were also  not straight.  Nevertheless, it is 
apparent that the decay was accelerated by rsCrry/p65 (Fig. 
4).  However, ten times as much rsCrry/p65 was necessary 
for significant acceleration of decay of the alternative pathway 
C3 convertase than for the classical pathway C3 convertase. 
Species Specificity of Crry/p65 Activity.  Human comple- 
ment regulatory proteins that protect host ceils often show 
species specificity,  that is they are inactive against heterolo- 
gous complement. We tested whether Crry/p65 has this char- 
acteristic of stir-protecting complement regulatory proteins. 
As shown in Fig.  5, the combination of mouse factor I and 
Crry/p65 did not cleave human C3b (Fig.  5, lane e).  Since 
mouse factor I had ability to cleave human C3b with human 
factor H  (Fig.  5, lane k), this indicates that Crry/p65 is in- 
compatible with human C3b.  The combination of human 
factor I and Crry/p65 did not cleave either mouse C3b  or 
Figure 5.  Species  specificity  ofCrry/p65. Species  specificity  ofcofactor 
activity of Crry/p65 was tested using combinations of C3b and factor I 
of human (hu) and mouse (mo) origins. Radiolabeled mouse C3b (lanes 
a-c) and radiolabded human C3b (lanes  d-h) were incubated with Crry/p65 
and either mouse or human factor I at 37~  for 1 h. Cleavage of the c~ 
chains was then assessed  by SDS-PAGE  and autoradiography. (Lanes  a and 
d) C3b alone; (lanes b and e) mouse factor I and Crry/p65;  (lanes c and 
J) human factor I and Crry/p65; (laneg) human factor I and human factor 
H; (lane h) mouse factor I and human factor H. human C3b (Fig. 5, lanes c andJ), indicating that Crry/p65 
is incompatible with human factor I. Thus, cofactor activity 
of Crry/p65  is restricted to homologous complement. 
Discussion 
In these studies we have characterized the molecular mech- 
anisms of intrinsic membrane complement regulation by the 
Crry/p65 protein of the mouse RCA family. Surprisingly, 
this one mouse protein, Crry/p65, uses the specific comple- 
ment regulatory mechanisms of both human DAF and MCP. 
Crry/p65 acts as a decay-accelerator in addition to a factor 
I cofactor, and it can perform these activities in both C3 and 
C4 dependent systems. The net result of these regulatory ac- 
tivities is self-protection of cells from untoward activation 
of either the classical or alternative pathway. Crry/p65 is a 
widely distributed protein,  as are DAF and MCP in toto. 
Crry/p65 also demonstrates species restriction. Based on these 
similarities  in function and sites of expression, in addition 
to the lack of detection of DAF and MCP related genes, we 
believe that Crry/p65 performs many if not all of the same 
biologic roles in mouse as DAF and MCP in humans. In this 
light, the lack of detectable crosshybridization in mouse by 
human DAF and MCP cDNAs is not entirely surprising. 
We do not currently have an explanation for one previous 
study in which a purified GPI-anchored mouse erythrocyte 
protein was reported to have decay-accelerating activity for 
both  mouse  C3/C5  convertases and  the  human  classical 
pathway C3 convertase (32). A polyclonal antibody reported 
to be reactive with that protein failed to stain our K562 cells 
expressing Crry/p65 (Okada, H., and V. M. Holers, unpub- 
lished observations). In addition, our previous studies have 
not detected release of Crry/p65 from mouse erythrocytes 
or splenocytes by PIPLC under the same conditions used to 
release Thy-1 in parallel (15). Resolution of this issue awaits 
the identification of the gene encoding this putative GPI- 
anchored complement regulatory protein followed by a com- 
parison to Crry/p65. Pertinent to this issue, our studies cannot 
rule out the presence of other membrane proteins in mouse 
with complement regulatory activity acting at the C3/C5 
convertase steps. 
In these studies, we have also compared the activities of 
Crry/p65 with MCR1.  There are important differences be- 
tween the two proteins. Crry/p65 demonstrates cofactor ac- 
tivity for mouse factor I-mediated cleavage of both mouse 
C3b and C4b. In addition, Crry/p65 protects cells from C3 
deposition resulting from both classical and alternative pathway 
activation. In our current study, however, MCR1 manifests 
no detectable cofactor activity for mouse factor I-mediated 
cleavage of mouse C4b, in spite of demonstrating this activity 
for mouse C3b under similar conditions. Membrane-bound 
MCR1  also does not effectively protect cells from classical 
pathway activation (12). These observations provide further 
support for our hypothesis that Crry/p65 is the primary in- 
trinsic membrane complement regulatory protein in mouse. 
We cannot yet in these studies determine a specific activity 
for Crry/p65 relative to MCR1. However, the absence of C4b 
cleavage by MCR1 when C3b cleavage is manifest by both 
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MCR1  and  Crry/p65,  and  the  easily demonstrable  C4b 
cleavage by Crry/p65, is an important consideration in com- 
paring the relative C3 versus C4 regulation by these two pro- 
teins.  These results suggest that Crry/p65 is overall a more 
potent complement regulatory protein. The lack of efficient 
factor I cofactor activity for mouse C4b exhibited by MCR1 
is also interesting in light of its apparent ability to act as a 
receptor for rat C4b-coated erythrocytes (33). 
With these experimental findings, obvious questions in- 
clude both how and why this difference between the mouse 
and human RCA gene families could have occurred during 
evolution. We believe that a comparison of the structures of 
the human and mouse genes provides a rational mechanism 
by which two evolutionary paths could have been taken. The 
structural relationships of RCA proteins and possible evolu- 
tionary relationships of human and mouse RCA genes en- 
coding CR1,  CR2,  and  Crry/p65  have been discussed in 
previous publications  (13, 14, 18). These analyses have demon- 
strated a relatively high degree of protein and nucleotide se- 
quence conservation and have suggested a linked evolution. 
For instance, the first four SCRs of the Crry/p65 protein 
are most similar in sequence to the first four SCRs of both 
MCR1 and human CR1. The 5th SCR of Crry/p65 is very 
similar to the 30th SCR of human CR1, both of which are 
the most membrane proximal SCRs. Human CR2 and CR1 
have sequence similarity (34, 35).  In addition, human CR2 
and MCR2 sequences are ~70% identical (13, 14), and the 
human CR2 gene contains nonexpressed nucleotide sequences 
apparently derived from expressed exons within the Cr2 gene 
encoding the first six SCRs of MCR1 (36). The mouse RCA 
genes encoding Cr2 and Crry have also apparently undergone 
a translocation and/or inversion resulting in the movement 
of these two genes ~40 cM away from the comparable loca- 
tion in the human genome (37). 
For the present comparison, we have taken further advan- 
tage of one characteristic feature of SCR-containing genes 
that has greatly facilitated the analysis  of the evolution of 
RCA genes. That feature is the different type of exon that 
encodes each SCR. SCRs are found to be encoded either on 
a single exon, as a pair of SCRs on a single exon, or as a 
split SCR encoded on two separate exons (10, 27).  In each 
exon type in all of the RCA genes, the phase of exon-intron 
junctions are completely conserved. To obtain this informa- 
tion with the goal of further understanding the evolution 
of the human and mouse RCA genes, we have determined 
the rest of the exon structure of the Cr2 gene encoding the 
first  six SCRs of MCR1. 
Results  of this  analysis  are included in  Table  2  and in 
schematic fashion in Fig. 6.  The Cr2 SCR organization is 
shown compared with the previously determined Crry gene 
organization (38) in addition to human CR1 (39), CR2 (27), 
DAF (40),  and MCP (3).  In this figure, we have included 
22 SCRs in the mouse Cr2 gene in order to include the alter- 
natively spliced exon in the human CR2 gene, as it is likely 
that at least a remnant of that exon is present in the mouse 
(14). What is readily apparent is the presence of a module 
encoding four SCRs (Fig.  6, bracket). This module consists 
of a motif of exons encoding a single SCR followed by a 
Protein Crry/p65 Table 2.  Cr2 Exon-Intron Junction Sequences 
Exon  Junctions 
1  tatttctag/GT  CAG. 
2A  cccttgtag/GT  AAA. 
2B  tagttctag/A  TAT. 
3,4  cctccaaag/CT ATT. 
5  ttcttgtag/GA  TGT. 
6A  tttccctag/TG  AAA. 
AAA  C/gtgagtacttct 
CAAGG/gtgagtaggcag 
GAA  T/gtagataaaatg 
ATG  G/gtaagttgggcc 
GAA  G/gtgcttagagct 
TTA GG/gtgagtgtgaag 
Exon-intron junctions of exons encoding  the first 5.5 SCRs of MCR1. 
These sequence data  are available from EMBL/GenBank/DDBJ under 
accession numbers U171123-8. 
split SCIL and then two fused SCRs and is found in each 
gene except DAF and MCP. Not surprisingly, the Crry/p65 
module is in the first four SCRs and includes the region of 
most sequence similarity to human CR1 and MCR1. This 
module is present as the first 4 SCRs of human CPd long 
homologous repeat (LHR) A, in which the C4b-binding site 
of human CRI is found (41, 42). C3b-binding sites are found 
in comparable sites of the highly repetitive LHRs B and C, 
and this module is also found at the same two sites. The first 
four SCRs of MCR1 also consist of this module and contain 
the C3b/C4b binding site in addition to the C3b cofactor 
site (33, 43). 
We propose that this four SCP,-containing module is a 
primordial C3b/C4b binding element that apparently evolved 
before speciation separating humans and mice. Subsequently, 
this module has evolved  into either a C3b and/or C4b receptor, 
or a C3/C4 regulatory protein, depending on the species  and 
Extracytoplasmic  RCA Genomic  Stuctures 
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Figure  6.  Exon-intron organization  of RCA genes encoding mouse 
and human membrane proteins. Bracket indicates four SCR-containing motif 
present in mouse Crry and Cr2 in addition to human CR1 and CR2. DAF 
and MCP lack the motif. Ligands that bind within the motifs are shown. 
The site of alternative  splicing within Cr2 gene between exons 6b and 
7,8 is shown by the Y. 
context in which it is found. In some locations, such as LHR 
D of human CR1 and the membrane proximal modules of 
MCR1 and CR2, no C3b or C4b binding is detected. How- 
ever, one module of CR2 demonstrates C3d binding within 
one fused SCR exon (Fig. 6). Crry/p65 demonstrates the most 
extensive binding and regulatory activity found to date that 
is likely to be conserved within a single modular element. 
Only one other member of the RCA family, human CR1, 
has both decay-accelerating and factor I cofactor activity. Al- 
though the C3 and C4 binding and regulatory sites are non- 
overlapping and contained in separate modules, it is of some 
interest also that Crry/p65 was first recognized by its cross- 
reactivity with anti-human CR1 antibody and its crosshybridi- 
zation with human CR1 cDNA. 
Thus, our results strongly support the hypothesis that in 
mouse and in humans two different evolutionary paths were 
taken. The apparent loss of MCP and DAF in the murine 
lineage may have, in part, been driven by the opportunistic 
use of MCP and/or DAF by human pathogens.  In humans, 
MCP is the primary receptor for the measles virus (44, 45), 
and DAF may be an Escherichia  coli receptor  (46). Certain 
mouse cells can only be infected by the measles virus after 
transfection of recombinant MCP (45). Therefore, driven by 
this type of evolutionary pressure, a partial  duplication  of 
Cr2 may alone have eventually generated the Crry/p65 mol- 
ecule that could provide the same self-protection on cell mem- 
branes of mice as DAF and MCP do in humans. 
We cannot yet devise a molecular model of evolution that 
incorporates all of the RCA family membrane bound receptors 
and regulatory proteins. Molecular analyses of DAF, MCP, 
CR1, CR2, and Crry/p65 homologous in other species should 
continue to be instructive in this regard and will allow the 
further refinement  of evolutionary models. In this regard, 
a Crry/p65 homologue in rat has recently been identified and 
partially sequenced (47, 48). This rat protein also exhibits 
complement regulatory activity. Based on the common SCR 
structures  and biochemical activities, it is likely that DAF 
and MCP as well as Crry/p65 share a more distant  evolu- 
tionary progenitor. Whatever the results of those future anal- 
yses, it is already apparent that the repetitive SCR containing 
structure of the RCA genes has allowed a unique evolutionary 
process to proceed. 
Finally, we believe that mouse Crry/p65 can serve as an 
effective model for the biologic activities of DAF and MCP. 
In addition to the protection of normal cells from inadver- 
tent complement pathway activation, several other biologic 
roles have been proposed  for the normal expression or, in 
some cases, the overexpression complement regulatory pro- 
teins. These roles include the protection of  placenta and fetus 
from complement fixing "alloantibody" (49), sperm from anti- 
sperm antibodies and complement in the female reproduc- 
tive tract (50), tumors from antitumor antibody (26), and 
normal cells from NK activity (51). Analysis of the in vivo 
role of Crry/p65 in various mouse models should further in- 
crease our understanding of the biologic roles of membrane 
complement regulatory proteins. 
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